The Saudi Food & Drug Authority (SFDA) hosts the Generic Products Quality Day on Tuesday, 29 September 2026, at the Training Hall (Gate 1) of the SFDA Main Building in Riyadh. Running from 10:00 AM to 3:00 PM, this one-day scientific meeting brings regulators, pharmaceutical manufacturers, quality professionals, and pharmacists together around a single theme: the quality of generic medicines circulating in the Saudi market and the regulatory expectations behind them.
Generic medicines account for a growing share of prescriptions in Saudi Arabia and are central to Vision 2030's goals of localising pharmaceutical manufacturing and improving access to affordable, high-quality therapy. This event is designed as a direct channel between the SFDA's Generic Products Directorate and the industry it regulates — a chance to hear how quality evaluation decisions are made, where dossiers most commonly fall short, and how new guidance is expected to be applied in practice.
Programme highlights
The day opens with an Opening Ceremony led by Dr. Adel Al Harf (Vice President for the Drug Sector), Dr. Saeed Al Awadh (Executive Director of Quality Evaluation of Medicines), and Ibrahim H. Mujammami (Director of the Generic Products Directorate).
Dr. Turki Alhagbani, Senior Chief Scientific Evaluation Expert, then presents "Quality Generic Medicines: Creating Healthcare Value", framing how consistent quality standards translate into clinical confidence, prescriber trust, and system-level cost savings.
A dedicated explanatory session on the guideline covering quality requirements for synthetic peptides follows, delivered by Dr. Naiqi Ya (Consultant, Executive Directorate for Quality Evaluation of Medicines) and Areej Alsuwayyid (Senior Scientific Evaluation Expert). Synthetic peptide products are one of the fastest-moving segments in generic and hybrid development, and this session walks through the documentation, characterisation, and impurity control expectations attached to them.
After the break, the afternoon is given to roundtable sessions with experts from the Generic Products Directorate — an open, discussion-led format where attendees can raise submission scenarios, evaluation queries, and practical compliance challenges directly with the reviewers who assess them. Ibrahim H. Mujammami closes the day.
Who should attend
Regulatory affairs professionals, quality assurance and quality control specialists, pharmaceutical manufacturers and local producers, hospital and community pharmacists, bioequivalence and CRO scientists, pharmaceutical scientists in academia, and anyone preparing generic or peptide product dossiers for the Saudi market.
Format and access
The event is held in person at the SFDA Main Building in Riyadh with limited seating in the Training Hall (Gate 1). Registration is handled via the SFDA sign-up channel published on the official agenda; interested attendees should register early, as capacity for on-site regulatory days of this kind is typically constrained. Follow @Saudi_FDA or visit www.sfda.gov.sa for confirmation of registration links and any programme updates.
